An interventional study of Medisinstart in Cardiovascular Diseases, sponsored by Apokus AS. Completed at 67 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-20.
Sponsored by Apokus AS · Not applicable, Interventional, and Supportive care
"Medisinstart" is a new service developed for use in Norwegian pharmacies. It is intended for patients that are about to start a new medicine for a chronic or long-term condition. It is based on research showing that problems with newly prescribed medicines appear rapidly and that a significant portion of patients quickly becomes non-adherent. The service consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
The main purpose of this study is to investigate whether "Medisinstart" increases patients' adherence to the prescribed medication. Patients' beliefs about their medicines and their motivation for adherence will also be examined. The study also aims at revealing if "Medisinstart" has additional benefits for the patient, the society and the pharmacies.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's enrollment of 1,480 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Apokus AS is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
First time prescription for a drug belonging to one of the following groups (ATC-code):
Exclusion Criteria:
Patients in this arm will receive the service; Medisinstart
Other: Medisinstart
Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
"Medisinstart" is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine.
Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 7 weeks
Adherence will be measured by a validated Norwegian translation of the MMAS-8
Time frame: 7 weeks after dispensing the new medicine
Adherence by Morisky 8-item Medication Adherence Scale (MMAS-8) at 18 weeks
Adherence will be measured by a validated Norwegian translation of the MMAS-8
Time frame: 18 weeks after dispensing the new medicine
Self reported adherence at 7 weeks
Adherence will be measured by a Norwegian translation of the question: "People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week?"
Time frame: 7 weeks after dispensing the new medicine
Adherence by Medication Possession Ratio (MPR) at 18 weeks
Adherence by MPR will be calculated from data collected from the Norwegian Prescription Database
Time frame: 18 weeks after dispensing the new medicine
Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at inclusion
Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ
Time frame: At inclusion
Self reported adherence at 18 weeks
Adherence will be measured by a Norwegian translation of the question: "People often miss taking doses of their medicines, for a wide range of reasons. Have you missed any doses of your new medicine the last week?"
Time frame: 18 weeks after dispensing the new medicine
Adherence by Medication Possession Ratio (MPR) at 1 year
Adherence by MPR will be calculated from data collected from the Norwegian Prescription Database
Time frame: 1 year after dispensing the new medicine
Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 7 weeks
Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ
Time frame: 7 weeks after dispensing the new medicine
Patients' beliefs about their medicines by Beliefs about Medicines Questionnaire (BMQ) at 18 weeks
Patients' beliefs about their medicines will be measured by a validated Norwegian translation of the BMQ
Time frame: 18 weeks after dispensing the new medicine
Number of reported Medication-Related Problems in the intervention arm
The pharmacist carrying out the intervention will report all discovered Medication-Related Problems
Time frame: During the intervention
Patients' evaluation of "Medisinstart"
Patients' in the intervention arm will evaluate the service by answering a questionnaire
Time frame: 7 weeks after dispensing the new medicine
Pharmacists' evaluation of patient benefit
Pharmacists performing the service will answer the following question (translated from Norwegian): "You have currently performed "Medisinstart" with at least 5 patients. Do you regard it to be beneficial for the patients?"
Time frame: 7 months after start of the study
Pharmacy costs by performing the service
Pharmacies will report the COSTs for carrying out the service
Time frame: 1 year after study start
Plan to share: No
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Apokus AS